EGFR and metastatic colorectal cancer: For example, Cetuximab and Panitumumab were originally approved (in 2004 and 2006 respectively) to target the epidermal growth factor receptor (EGFR) which may be overexpressed in patients with metastatic colorectal cancer (mCRC) [2].